A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- Drug: AZD4512
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 91
- Registration Number
- NCT07123454
- Locations
- 🇬🇧
Research Site, Newcastle-Upon-Tyne, United Kingdom
Surveillance Trial of the Apple Watch in Reliable Burden Assessment in Unseen Recurrence of Surgically Treated AF
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 75
- Registration Number
- NCT07122947
- Locations
- 🇺🇸
Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain
- Conditions
- Lower Back Pain
- Interventions
- Drug: CNTX-3001Drug: Placebo
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Centrexion Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT07122453
- Locations
- 🇺🇸
Neurovations, Napa, California, United States
Demographics of Lung Cancer in Females
- Conditions
- Lung Cancer
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Mansoura University Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT07122245
- Locations
- 🇪🇬
Mohamed AbdElmoniem, Mansoura, Egypt
A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors
- Conditions
- Advanced Malignancy
- Interventions
- Drug: SHR-7782 Injection
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT07123129
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Cannabis Impairment Detection Device Study
- Conditions
- Cannabis Intoxication
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Gaize
- Target Recruit Count
- 362
- Registration Number
- NCT07122349
- Locations
- 🇨🇦
Dicentra, Toronto, Ontario, Canada
To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia
- Conditions
- Chronic Postoperative Neuralgia
- Interventions
- Drug: TRD205 tabletsDrug: Placebo
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 184
- Registration Number
- NCT07123402
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
Cross-sectional Study of Sleep Disturbance in Hong Kong Children With Cancer Comparing With Healthy Counterparts and Children With Other Chronic Diseases
- Conditions
- SleepSleep Disturbances in ChildrenSleep Disturbances
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 150
- Registration Number
- NCT07122921
- Locations
- 🇭🇰
Hong Kong Children's Hospital, Hong Kong, Hong Kong
Bioequivalence Assessment Between Two Cariprazine Hard Capsule Formulations
- Conditions
- Bioequivalence Study in Healthy Subjects
- Interventions
- Drug: Test Product (Vocarzine)Drug: Reference (R) Reagila ®
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Aya Mohammed Abdel Magid Abdel Hamid
- Target Recruit Count
- 29
- Registration Number
- NCT07121868
- Locations
- 🇪🇬
Advanced Research Center (ARC), Cairo, Egypt
Emotional Suppression in Elderly Individuals
- Conditions
- Elderly Person
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Istinye University
- Target Recruit Count
- 50
- Registration Number
- NCT07122817
- Locations
- 🇹🇷
Istinye University, Istanbul, Turkey